In conjunction with this financing, Anders Hove of Venrock Associates and Myles Greenberg of CHL Medical Partners will join Still River Systems’s board of directors.
Still River Systems said that the proceeds from this financing will accelerate the development of its Monarch250 Proton Therapy System.
Marc Buntaine, CEO of Still River Systems, said: “Completion of this financing illustrates the investment community’s confidence in Still River’s business model and our ability to execute on our plan. We are pleased with the continued participation of our existing investors and warmly welcome our new investor partners, Venrock Associates and CHL Medical Partners.”